Circulating metabolites associated with incident myocardial infarction and stroke: A prospective cohort study of 90 438 participants
暂无分享,去创建一个
W. Cheng | Huifu Wang | Q. Dong | Shidong Chen | Shu-fen Chen | Shue Huang | Ya-Ru Zhang | Bang-Sheng Wu | Yue-Ting Deng | Jian-Feng Feng | Jin-Tai Yu | Yu Guo | Kevin Kuo | Rong-Ze Wang | Jianfeng Feng | K. Kuo | Yaru Zhang | Ya‐Ru Zhang
[1] E. Boerwinkle,et al. Metabolomic Pattern Predicts Incident Coronary Heart Disease. , 2019, Arteriosclerosis, thrombosis, and vascular biology.
[2] E. Rimm,et al. Predicted lean body mass, fat mass, and all cause and cause specific mortality in men: prospective US cohort study , 2018, British Medical Journal.
[3] R. Collins,et al. Lipids, Lipoproteins, and Metabolites and Risk of Myocardial Infarction and Stroke , 2018, Journal of the American College of Cardiology.
[4] L. Liang,et al. Plasma lipidomic profiles and cardiovascular events in a randomized intervention trial with the Mediterranean diet. , 2017, The American journal of clinical nutrition.
[5] Cathie Sudlow,et al. UK Biobank: opportunities for cardiovascular research , 2017, European heart journal.
[6] Debbie A Lawlor,et al. Quantitative Serum Nuclear Magnetic Resonance Metabolomics in Large-Scale Epidemiology: A Primer on -Omic Technologies , 2017, American journal of epidemiology.
[7] Xiaoke Yin,et al. Very-Low-Density Lipoprotein–Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III , 2017, Journal of the American College of Cardiology.
[8] Brian A Ference,et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. , 2016, JAMA.
[9] S. Humphries,et al. Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes. , 2016, JAMA cardiology.
[10] J. Polak,et al. Concentration of Smaller High‐Density Lipoprotein Particle (HDL‐P) Is Inversely Correlated With Carotid Intima Media Thickening After Confounder Adjustment: The Multi Ethnic Study of Atherosclerosis (MESA) , 2016, Journal of the American Heart Association.
[11] R. Brook,et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. , 2015, Journal of the American College of Cardiology.
[12] Tom R. Gaunt,et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. , 2015, Circulation.
[13] Pasi Soininen,et al. Quantitative serum nuclear magnetic resonance metabolomics in cardiovascular epidemiology and genetics. , 2015, Circulation. Cardiovascular genetics.
[14] T. Spector,et al. Lipidomics Profiling and Risk of Cardiovascular Disease in the Prospective Population-Based Bruneck Study , 2014, Circulation.
[15] Tom R. Gaunt,et al. Mendelian randomization of blood lipids for coronary heart disease , 2014, European heart journal.
[16] Xiang Wang,et al. Cholesterol Levels and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis , 2013, Stroke.
[17] Jian Chen,et al. Enhanced Neuroprotection by Local Intra-Arterial Infusion of Human Albumin Solution and Local Hypothermia , 2013, Stroke.
[18] R. Collins,et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials , 2012, The Lancet.
[19] R. Collins,et al. Lipids and Lipoproteins and Risk of Different Vascular Events in the MRC/BHF Heart Protection Study , 2012, Circulation.
[20] J. Mckenney,et al. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). , 2008, The American journal of cardiology.
[21] R. Collins,et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths , 2007, The Lancet.
[22] Inder Singh,et al. High-density lipoprotein as a therapeutic target: a systematic review. , 2007, JAMA.
[23] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[24] A. Kontush,et al. Small, Dense HDL Particles Exert Potent Protection of Atherogenic LDL Against Oxidative Stress , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[25] E. Bolson,et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.
[26] R. Busto,et al. Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies. , 2001, European journal of pharmacology.
[27] P. Pattany,et al. Diffusion-weighted magnetic resonance imaging confirms marked neuroprotective efficacy of albumin therapy in focal cerebral ischemia. , 1998, Stroke.
[28] M D Ginsberg,et al. Effect of delayed albumin hemodilution on infarction volume and brain edema after transient middle cerebral artery occlusion in rats. , 1997, Journal of neurosurgery.
[29] B. J. Gersh. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2011 .
[30] G. Moneta,et al. Major Lipids, Apolipoproteins, and Risk of Vascular Disease , 2010 .
[31] C. Knoop,et al. Drug treatment of lipid disorders. , 1999, The New England journal of medicine.
[32] T. Asano,et al. Beneficial effect of prolonged administration of albumin on ischemic cerebral edema and infarction after occlusion of middle cerebral artery in rats. , 1993, Neurosurgery.